TNGX: Falling Wedge detected on 30 Oct 2026

TNGX is forming a falling wedge pattern with moderate technical quality (overall score: 61.92). The stock is trading at $22.53, centered in its wedge between key support at $20.68 and resistance at $24.18. Structure scores 14/15, but volume support is weak at 7/12, suggesting below-average participation (current volume 3.37M vs. 20-day average 4.65M, volume ratio 0.73). Breakout strength scores 11.92/13, indicating the narrowing pattern is developing but lacks conviction. RSI sits at 45.94 (neutral), MACD histogram is negative (-0.1064), and the stock trades 34% below its 52-week high after falling 19% in one week.

Tango presented positive vopimetostat combination data on October 23, 2026, and Stifel raised its price target to $55 from $40 on the same date. However, the stock fell 18% to $22.91 on October 25 after ESMO presentation showed a lower pancreatic cancer response rate than June data. Canaccord Genuity maintained a Buy rating on October 26, and HC Wainwright maintained a $68 price target on October 29. Counterbalancing this, Zacks downgraded TNGX to 'strong sell' from 'hold' on October 29. The company recently reported a quarterly loss of $0.37 per share, missing the $0.32 consensus estimate. Insiders recently sold shares, while institutional investors own 78.99%.

A successful breakout above $24.18 would target the conservative price objective of $23.60 initially, with higher technical resistance near the pattern midline. However, the wedge's modest breakout score (11.92/13) and weak volume (0.73x normal) suggest limited momentum confirmation. The 72.29% win probability indicates the setup has favorable odds statistically, but execution depends on volume expansion above the 4.65M 20-day average. Invalidation occurs at support break of $20.68, which would represent a 8.2% downside from current price. The wedge structure suggests potential for 5-8% upside if the breakout holds.

Multiple catalysts create elevated near-term risk. On October 22, the board approved a plan to cut about 14% of the workforce, mostly in research, and deprioritize novel target discovery. Clinical data disappointment is a material risk—the October 25 ESMO presentation showed declining response rates versus June guidance, which contributed to the 19% one-week loss. The recent Zacks downgrade to 'strong sell' indicates analytical consensus weakness. High beta (1.44) amplifies volatility in a volatile biotech sector. Volume deficit (0.73x average) signals weak institutional support at current levels. Negative MACD histogram and below-average RSI suggest momentum headwinds despite sector tailwinds (healthcare regime bullish at +0.81). Clinical trial progression risk and cash burn remain inherent biotech concerns.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.